Exelixis Inc - fluxo de caixa trimestral (NASDAQ:EXEL) | MetaTrader

Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas

Cash from operating activities 333.51 M 884.27 M Cash from investing activities 27.24 M 350.44 M Cash from financing activities -254.57 M -969.59 M Free cash flow 332.36 M 875.84 M

Exelixis Inc

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

Notícias

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Exelixis (EXEL) Down 2.8% Since Last Earnings Report: Can It Rebound?

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Exelixis, Inc. (EXEL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Exelixis na conferência de saúde da Barclays: crescimento estratégico e insights do pipeline

Exelixis at Barclays Healthcare: Strategic Growth and Pipeline Insights

Exelixis apresenta insights estratégicos em RCC e CRC na conferência Leerink

Exelixis at Leerink Global Healthcare Conference: Strategic Insights in RCC and CRC

Exelixis, Inc. (EXEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Exelixis at TD Cowen: Strategic Vision and Growth

Ações da Exelixis caem após resultados superiores em teste da rival Merck

Exelixis stock falls after rival Merck trial shows better results